Skip to main content

Table 2 Main characteristics of eligible studies for diagnosis

From: Circulating long noncoding RNAs as potential biomarkers for stomach cancer: a systematic review and meta-analysis

First author, year

Race

Pathologictype (E/C)

Sample size (E/C)

Specimen

lncRNA

State

Sen

Spe

TP

FP

FN

TN

QUADAS-2

(Refs)

Liu, 2019

Asian

GC/HD

89/73

Serum

FEZF1-AS1

Up

75.3%

65.8%

67

25

22

48

5

[15]

    

AFAP1-AS1

Up

76.4%

56.2%

68

32

21

41

  

Yoruke, 2018

Caucasian

GC/non-GC

40/42

Plasma

H19

Up

87.2%

38.1%

35

26

5

16

6

[16]

Liu, 2019

Asian

GC/HD

100/100

Serum

MALAT1

Up

85.8%

74.5%

86

26

14

75

4

[17]

Hashad, 2016

Caucasian

GC/HD

32/30

Plasma

H19

Up

68.8%

56.7%

22

13

10

17

5

[18]

Li, 2014

Asian

GC/HD

79/81

Plasma exosome

LINC00152

Down

48.1%

85.2%

38

12

41

69

6

[19]

Liu, 2014

Asian

GC/HD

83/80

Plasma

FER1L4

Up

67.2%

80.3%

56

16

27

64

7

[20]

Liu, 2018

Asian

GC/HD

50/50

Plasma

CTC-501O10.1

Up

90.0%

51.0%

45

25

5

26

6

[21]

    

AC100830.4

Up

84.0%

58.0%

42

21

8

29

  
    

RP11-210K20.5

Up

89.0%

55.0%

45

23

6

28

  

Lu, 2017

Asian

EGC/HD

76/76

Serum

XIST

Up

84.6%

59.0%

64

31

12

45

5

[22]

    

BCYRN1

Up

67.9%

85.9%

52

11

24

65

  
    

RRP1B

Down

85.9%

56.4%

65

33

11

43

  
    

TDRG1

Down

73.1%

60.3%

56

30

20

46

  

Mohamed, 2019

Caucasian

GC/HD

35/25

Serum

H19

Up

90.9%

100.0%

32

0

3

25

5

[23]

Piao, 2020

Asian

GC/HD

281/80

Plasma exosome

CEBPA-AS1

Up

74.0%

88.0%

208

10

73

70

6

[24]

Zhou, 2016

Asian

GC/HD

77/60

Plasma

ZFAS1

Up

76.6%

63.9%

59

22

18

38

5

[25]

Cai, 2019

Asian

GC/HD

63/29

Serum exosome

PCSK2-2:1

Up

84.0%

86.5%

53

4

10

25

6

[26]

Zhou, 2015

Asian

GC/HD

90/90

Plasma

H19

Up

82.9%

72.9%

75

24

15

66

7

[27]

Elsayed, 2018

Caucasian

GC/HD

50/50

Plasma

HOTAIR

Up

86.0%

94.0%

43

3

7

47

4

[28]

Xian, 2018

Asian

GC/HD

50/50

Plasma

HULC

Up

58.0%

80.0%

29

10

21

40

5

[29]

    

ZNFX1-AS1

Up

84.0%

68.0%

42

16

8

34

  

Feng, 2019

Asian

GC/HD

107/87

Serum

B3GALT5-AS1

Up

64.5%

87.4%

69

11

38

76

5

[30]

Fu, 2017

Asian

GC/HD

72/72

Serum

LINC00978

Up

80.0%

70.0%

58

22

14

50

5

[31]

Gao, 2015

Asian

GC/HD

20/20

Plasma

UCA1

Up

85.0%

96.3%

17

1

3

19

6

[32]

    

PVT1

Down

70.8%

91.3%

14

2

6

18

  

Ghaedi, 2018

Asian

GC/HD

62/40

Plasma

H19

Up

74.2%

90.0%

46

4

16

36

6

[33]

    

MEG3

Down

77.4%

52.5%

48

19

14

21

  

Guo, 2020

Asian

EGC/HD

217/219

Plasma exosome

GC1

Up

97.0%

83.0%

210

37

7

182

5

[34]

Arita, 2013

Asian

GC/HD

43/34

Plasma

H19

Up

74.0%

58.0%

32

14

11

20

6

[35]

Ji, 2019

Asian

GC/HD

168/74

Plasma

LINC00086

Down

72.6%

83.8%

122

12

46

62

7

[36]

Jiang, 2019

Asian

GC/HD

317/100

Plasma

PCGEM1

Up

72.9%

88.9%

231

11

86

89

7

[7]

Lin, 2018

Asian

GC/HD

51/60

Plasma exosome

UEGC1

Up

88.0%

82.0%

45

11

6

49

5

[37]

    

UEGC2

Up

89.0%

58.0%

45

25

6

35

  

Pan, 2017

Asian

GC/HD

60/37

Serum exosome

ZFAS1

Up

71.7%

75.7%

43

9

17

28

5

[38]

Jin, 2016

Asian

GC/HD

173/110

Serum

HULC

Up

82.0%

83.6%

142

18

31

92

6

[39]

Zhang, 2018

Asian

GC/HD

57/29

Serum exosome

UFC1

Up

78.0%

80.0%

44

6

13

23

5

[2]

Zhao, 2018

Asian

GC/HD

126/120

Serum exosome

HOTTIP

Up

69.8%

85.0%

88

18

38

102

4

[40]

Burock, 2015

Caucasian

GC/non-GC

76/54

Plasma

MACC1

Up

68.0%

89.0%

52

6

24

48

5

[41]

Ke, 2017

Asian

GC/HD

51/53

Plasma

INHBAAS1

Down

92.7%

74.5%

47

14

4

39

6

[42]

    

MIR4435-2HG

Down

90.2%

74.5%

46

14

5

39

  
    

CEBPA-AS1

Down

78.0%

76.6%

40

12

11

41

  
    

UCA1

Down

73.2%

82.3%

37

9

14

44

  
    

AK001058

Down

95.1%

72.3%

49

15

2

38

  
  

47/52

Plasma

INHBAAS1

Down

82.7%

59.6%

39

21

8

31

  
    

MIR4435-2HG

Down

65.4%

87.2%

31

7

16

45

  
    

CEBPA-AS1

Down

96.2%

57.4%

45

22

2

30

  
    

AK001058

Down

76.9%

92.3%

36

4

11

48

  

Liu, 2019

Asian

GC/HD

94/40

Serum

HOXA11-AS

Up

78.7%

97.8%

74

1

20

39

7

[43]

Shan, 2019

Asian

GC/HD

117/100

Serum

UCA1

Up

93.2%

78.6%

109

21

8

79

6

[44]

Shao, 2016

Asian

GC/HD

83/90

Plasma

RMRP

Down

59.1%

67.8%

49

29

34

61

5

[45]

Yang, 2019

Asian

GC/HD

109/106

Plasma

FOXD2-AS1

Up

83.0%

50.0%

90

53

19

53

5

[46]

    

PANDAR

Up

85.0%

63.0%

93

39

16

67

  
    

SMARCC2

Up

90.0%

55.0%

98

48

11

58

  

Xu, 2020

Asian

GC/HD

109/50

Serum

MIAT

Up

81.5%

87.5%

89

6

20

44

5

[47]

Xu, 2018

Asian

GC/HD

34/34

Plasma

DGCR5

Down

58.0%

87.0%

20

4

14

30

6

[48]

Xu, 2019

Asian

GC/HD

45/45

Plasma

LINC01225

Up

50.0%

90.0%

23

5

23

41

4

[49]

Yang, 2016

Asian

GC/HD+GS

133/152

Serum

H19

Up

65.0%

53.0%

86

71

47

81

7

[50]

    

LINC00152

Up

40.0%

72.0%

53

43

80

109

  

Zheng, 2020

Asian

GC/HD

60/60

Plasma

SLC2A12-10:1

Up

68.0%

75.0%

41

15

19

45

5

[51]

Zheng, 2018

Asian

GC/HD

241/228

Plasma

FAM49B-AS

Up

58.0%

60.0%

140

91

101

137

6

[52]

    

GUSBP11

Up

46.0%

75.0%

111

57

130

171

  
    

CTDHUT

Up

73.0%

65.0%

176

80

65

148

  

Zhou, 2020

Asian

GC/GS+GA+GD

200/278

Serum

C5orf66-AS1

Down

77.5%

53.6%

155

129

45

149

6

[53]

Tan, 2016

Asian

GC/HD

117/80

Plasma

GACAT2

Down

87.2%

28.2%

102

57

15

23

5

[54]

  1. E/C experimental group/control group, GC gastric cancer, EGC early gastric cancer, HD healthy donor individuals, GS superficial gastritis, GA atrophic gastritis, GD gastric dysplasia, SEN sensitivity, SPE specificity, TP true positive, FP false positive, FN false negative, TN true negative, QUADAS-2 Quality Assessment of Diagnostic Accuracy Studies 2